{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:16Z","timestamp":1792184656859,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003385","name":"Georg-August-Universit\u00e4t G\u00f6ttingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003385","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Starting in 2019, the 2014 German Guidelines for Anxiety Disorders (Bandelow et al. Eur Arch Psychiatry Clin Neurosci 265:363\u2013373, 2015) have been revised by a consensus group consisting of 35 experts representing the 29 leading German specialist societies and patient self-help organizations. While the first version of the guideline was based on 403 randomized controlled studies (RCTs), 92 additional RCTs have been included in this revision. According to the consensus committee, anxiety disorders should be treated with psychotherapy, pharmacological drugs, or their combination. Cognitive behavioral therapy (CBT) was regarded as the psychological treatment with the highest level of evidence. Psychodynamic therapy (PDT) was recommended when CBT was not effective or unavailable or when PDT was preferred by the patient informed about more effective alternatives. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) are recommended as first-line drugs for anxiety disorders. Medications should be continued for 6\u201312\u00a0months after remission. When either medications or psychotherapy were not effective, treatment should be switched to the other approach or to their combination. For patients non-responsive to standard treatments, a number of alternative strategies have been suggested. An individual treatment plan should consider efficacy, side effects, costs and the preference of the patient. Changes in the revision include recommendations regarding virtual reality exposure therapy, Internet interventions and systemic therapy. The recommendations are not only applicable for Germany but may also be helpful for developing treatment plans in all other countries.<\/jats:p>","DOI":"10.1007\/s00406-021-01324-1","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T18:55:38Z","timestamp":1633460138000},"page":"571-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["The German Guidelines for the treatment of anxiety disorders: first revision"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2511-3768","authenticated-orcid":false,"given":"Borwin","family":"Bandelow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia M.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Rudolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Wiltink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred E.","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"1324_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1177\/0004867418799453","volume":"52","author":"G Andrews","year":"2018","unstructured":"Andrews G, Bell C, Boyce P, Gale C, Lampe L, Marwat O, Rapee R, Wilkins G (2018) Royal australian and new zealand college of psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry 52:1109\u20131172","journal-title":"Aust N Z J Psychiatry"},{"key":"1324_CR2","first-page":"468","volume-title":"Deutsches instrument zur methodischen leitlinien-bewertung (delbi)","author":"\u00c4ZQ\/AWMF","year":"2008","unstructured":"\u00c4ZQ\/AWMF (2008) Deutsches instrument zur methodischen leitlinien-bewertung (delbi). AWMF, pp 468\u2013519"},{"key":"1324_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","volume":"28","author":"DS Baldwin","year":"2014","unstructured":"Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, Malizia A, McCrone P, Nabarro D, O\u2019Neill C, Scott J, van der Wee N, Wittchen HU (2014) Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the british association for psychopharmacology. J Psychopharmacol 28:403\u2013439","journal-title":"J Psychopharmacol"},{"key":"1324_CR4","volume-title":"Deutsche s3-leitlinie behandlung von angstst\u00f6rungen, version 2","author":"B Bandelow","year":"2021","unstructured":"Bandelow B, Aden I, Alpers GW, Benecke A, Benecke C, Beutel ME, Deckert J, Domschke K, Eckhardt-Henn A, Geiser F, Gerlach AL, Harfst TH, Hoffmann S, Hoyer J, Hunger-Schoppe C, Kellner M, K\u00f6llner V, Kopp I, Langs G, Liebeck H, Matzat J, Ohly M, R\u00fcddel HP, Rudolf S, Scheufele E, Simon R, Staats H, Str\u00f6hle A, Waldherr B, Wedekind D, Werner AM, Wiltink J, Wolters JP (2021) Deutsche s3-leitlinie behandlung von angstst\u00f6rungen, version 2. AWMF"},{"key":"1324_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/15622975.2016.1181783","volume":"17","author":"B Bandelow","year":"2016","unstructured":"Bandelow B, Baldwin D, Abelli M, Altamura C, Dell\u2019Osso B, Domschke K, Fineberg NA, Grunblatt E, Jarema M, Maron E, Nutt D, Pini S, Vaghi MM, Wichniak A, Zai G, Riederer P (2016) Biological markers for anxiety disorders, ocd and ptsd\u2014a consensus statement. Part i: neuroimaging and genetics. World J Biol Psychiatry 17:321\u2013365","journal-title":"World J Biol Psychiatry"},{"key":"1324_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/15622975.2016.1190867","volume":"18","author":"B Bandelow","year":"2017","unstructured":"Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, Cinosi E, Davies S, Domschke K, Fineberg N, Grunblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Strohle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P (2017) Biological markers for anxiety disorders, ocd and ptsd: a consensus statement. Part ii: neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry 18:162\u2013214","journal-title":"World J Biol Psychiatry"},{"key":"1324_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00406-014-0563-z","volume":"265","author":"B Bandelow","year":"2015","unstructured":"Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME (2015) The German guidelines for the treatment of anxiety disorders. Eur Arch Psychiatry Clin Neurosci 265:363\u2013373","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1324_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","volume":"17","author":"B Bandelow","year":"2015","unstructured":"Bandelow B, Michaelis S (2015) Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci 17:327\u2013335","journal-title":"Dialogues Clin Neurosci"},{"key":"1324_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/YIC.0000000000000078","volume":"30","author":"B Bandelow","year":"2015","unstructured":"Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D (2015) Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 30:183\u2013192","journal-title":"Int Clin Psychopharmacol"},{"key":"1324_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00406-018-0972-5","volume":"270","author":"B Bandelow","year":"2020","unstructured":"Bandelow B, Schuller K (2020) Mean age and gender distribution of patients with major mental disorders participating in clinical trials. Eur Arch Psychiatry Clin Neurosci 270:655\u2013659","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1324_CR11","unstructured":"Bandelow B, Wedekind D (submitted) Internet psychotherapeutic interventions for anxiety disorders\u2014a critical evaluation"},{"key":"1324_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"B Bandelow","year":"2008","unstructured":"Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Wfsbp Task Force on Treatment Guidelines for Anxiety O-C, Post-Traumatic Stress D, Zohar J, Hollander E, Kasper S, Moller HJ, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lepine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J (2008) World federation of societies of biological psychiatry (wfsbp) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders\u2014first revision. World J Biol Psychiatry 9:248\u2013312","journal-title":"World J Biol Psychiatry"},{"key":"1324_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1176\/ajp.155.5.603","volume":"155","author":"A Broocks","year":"1998","unstructured":"Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, Hillmer-Vogel U, Ruther E (1998) Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 155:603\u2013609","journal-title":"Am J Psychiatry"},{"key":"1324_CR14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00115-019-0678-6","volume":"90","author":"J Diemer","year":"2019","unstructured":"Diemer J, Zwanzger P (2019) development of virtual reality as an exposure technique. Nervenarzt 90:715\u2013723","journal-title":"Nervenarzt"},{"key":"1324_CR15","unstructured":"GIN (2012) Guidelines international network. https:\/\/g-i-n.net"},{"key":"1324_CR16","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65\u201370","journal-title":"Scand J Stat"},{"key":"1324_CR17","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa1312828","volume":"370","author":"KF Huybrechts","year":"2014","unstructured":"Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, Mogun H, Levin R, Kowal M, Setoguchi S, Hernandez-Diaz S (2014) Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 370:2397\u20132407","journal-title":"N Engl J Med"},{"key":"1324_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00115-013-3961-y","volume":"85","author":"F Jacobi","year":"2014","unstructured":"Jacobi F, Hofler M, Strehle J, Mack S, Gerschler A, Scholl L, Busch MA, Maske U, Hapke U, Gaebel W, Maier W, Wagner M, Zielasek J, Wittchen HU (2014) mental disorders in the general population: study on the health of adults in germany and the additional module mental health (degs1-mh). Nervenarzt 85:77\u201387","journal-title":"Nervenarzt"},{"key":"1324_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1017\/S0033291703001399","volume":"34","author":"F Jacobi","year":"2004","unstructured":"Jacobi F, Wittchen HU, Holting C, Hofler M, Pfister H, Muller N, Lieb R (2004) Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German health interview and examination survey (ghs). Psychol Med 34:597\u2013611","journal-title":"Psychol Med"},{"issue":"Suppl 1","key":"1324_CR20","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"14","author":"MA Katzman","year":"2014","unstructured":"Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada\/Association Canadienne des troubles a, McGill U, Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O\u2019Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR (2014) Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 14(Suppl 1):S1","journal-title":"BMC Psychiatry"},{"key":"1324_CR21","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMsa043266","volume":"352","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, Wang P, Wells KB, Zaslavsky AM (2005) Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 352:2515\u20132523","journal-title":"N Engl J Med"},{"key":"1324_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1001\/archpsyc.1994.03950010008002","volume":"51","author":"RC Kessler","year":"1994","unstructured":"Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of dsm-iii-r psychiatric disorders in the united states. Results from the national comorbidity survey. Arch Gen Psychiatry 51:8\u201319","journal-title":"Arch Gen Psychiatry"},{"key":"1324_CR23","volume-title":"Moh clinical practice guidelines\u2014anxiety disorders","author":"MOH","year":"2015","unstructured":"MOH (2015) Moh clinical practice guidelines\u2014anxiety disorders. Ministry of Health, Singapore"},{"key":"1324_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181fe7825","volume":"22","author":"D Moher","year":"2011","unstructured":"Moher D, Altman DG, Liberati A, Tetzlaff J (2011) Prisma statement. Epidemiology 22:128","journal-title":"Epidemiology"},{"key":"1324_CR25","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1007\/s10995-016-2038-5","volume":"20","author":"M Muzik","year":"2016","unstructured":"Muzik M, Hamilton SE (2016) Use of antidepressants during pregnancy?: what to consider when weighing treatment with antidepressants against untreated depression. Matern Child Health J 20:2268\u20132279","journal-title":"Matern Child Health J"},{"key":"1324_CR26","volume-title":"Social anxiety disorder: recognition, assessment and treatment (full guideline)","author":"NICE","year":"2013","unstructured":"NICE (2013) Social anxiety disorder: recognition, assessment and treatment (full guideline). The British Psychological Society"},{"key":"1324_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pharmthera.2012.03.008","volume":"135","author":"F Oyebode","year":"2012","unstructured":"Oyebode F, Rastogi A, Berrisford G, Coccia F (2012) Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther 135:71\u201377","journal-title":"Pharmacol Ther"},{"key":"1324_CR28","first-page":"127","volume":"21","author":"SL Prady","year":"2018","unstructured":"Prady SL, Hanlon I, Fraser LK, Mikocka-Walus A (2018) A systematic review of maternal antidepressant use in pregnancy and short- and long-term offspring\u2019s outcomes. Arch Womens Ment Health 21:127\u2013140","journal-title":"Arch Womens Ment Health"},{"key":"1324_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114046","volume":"302","author":"CP Ramos-Sanchez","year":"2021","unstructured":"Ramos-Sanchez CP, Schuch FB, Seedat S, Louw QA, Stubbs B, Rosenbaum S, Firth J, van Winkel R, Vancampfort D (2021) The anxiolytic effects of exercise for people with anxiety and related disorders: an update of the available meta-analytic evidence. Psychiatry Res 302:114046","journal-title":"Psychiatry Res"},{"key":"1324_CR30","volume-title":"A guideline developer\u2019s handbook (sign publication no. 50)","author":"SIGN","year":"2019","unstructured":"SIGN (2019) A guideline developer\u2019s handbook (sign publication no. 50). Scottish Intercollegiate Guidelines Network (SIGN), Edinburgh"},{"key":"1324_CR31","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3109\/15622975.2010.489620","volume":"11","author":"D Wedekind","year":"2010","unstructured":"Wedekind D, Broocks A, Weiss N, Engel K, Neubert K, Bandelow B (2010) A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. World J Biol Psychiatry 11:904\u2013913","journal-title":"World J Biol Psychiatry"},{"key":"1324_CR32","volume-title":"Tenth revision of the international classification of diseases, chapter v (f): mental and behavioural disorders (including disorders of psychological development). Clinical descriptions and diagnostic guidelines","author":"WHO","year":"1991","unstructured":"WHO (1991) Tenth revision of the international classification of diseases, chapter v (f): mental and behavioural disorders (including disorders of psychological development). Clinical descriptions and diagnostic guidelines. World Health Organization, Geneva"},{"issue":"Suppl 8","key":"1324_CR33","first-page":"24","volume":"63","author":"HU Wittchen","year":"2002","unstructured":"Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J (2002) Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63(Suppl 8):24\u201334","journal-title":"J Clin Psychiatry"},{"key":"1324_CR34","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00115-020-01051-3","volume":"92","author":"P Zwanzger","year":"2021","unstructured":"Zwanzger P, Singewald N, Bandelow B (2021) pharmacotherapy of anxiety disorders-guideline-conform treatment and new developments. Nervenarzt 92:433\u2013440","journal-title":"Nervenarzt"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-021-01324-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-021-01324-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-021-01324-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T04:04:24Z","timestamp":1652241864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-021-01324-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1007\/s00406-021-01324-1","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,5]]},"assertion":[{"value":"18 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants in the guideline panel have declared their conflicts of interest (e.g., having received lecture honoraria from drug manufacturers or being a leading member of a group which advocates a particular form psychotherapy school). The guideline committee undertook every effort to base its recommendations exclusively on objective evaluation of the scientific evidence. Participants with a relevant conflict of interest abstained when recommendations on the treatment in question came to vote. In the past 36\u00a0months, Dr Bandelow has been on the speakers\u2019 board for Janssen, Lilly, Pfizer, Roche and Schwabe on the advisory board for Cannaxan, Lundbeck and Pfizer. Dr Werner, Dr Kopp, Dr Rudolf, Dr Wiltink and Dr Beutel declare that no conflicts of interest exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}